Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

BACKGROUND: There is strong evidence that disease progression, drug response and overall clinical outcomes of CML disease are not only decided by BCR/ABL1 oncoprotein but depend on accumulation of additional genetic and epigenetic aberrations. DNA hydroxymethylation is implicated in the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Guru, Sameer Ahmad, Sumi, Mamta Pervin, Mir, Abdul Rashid, Beg, Mirza Masroor Ali, koner, Bidhan Chandra, Saxena, Alpana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008925/
https://www.ncbi.nlm.nih.gov/pubmed/35421941
http://dx.doi.org/10.1186/s12885-022-09481-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008925/
https://www.ncbi.nlm.nih.gov/pubmed/35421941
http://dx.doi.org/10.1186/s12885-022-09481-9

Ejemplares similares